Is Cosibelimab included in the reimbursement scope of national medical insurance?

Cosibelimab (Cosibelimab), as a new type of immune checkpoint inhibitor, has gradually attracted attention in the field of tumor treatment in recent years. The drug mainly achieves anti-tumor effects by blocking the PD-1/PD-L1 signaling pathway and restoring the patient's own immune system's ability to recognize and kill tumor cells. With its good therapeutic potential, cosibelimab has shown positive efficacy in clinical trials of a variety of solid tumors, especially in the fields of lung cancer, head and neck cancer, and cutaneous squamous cell carcinoma.

Although cosibelimab has been approved and gradually entered clinical use in many countries around the world, so far, the drug has not been included in China's national medical insurance directory. This means that when patients use the drug in China, they need to bear the relevant costs out of their own pocket, which has put great financial pressure on many patients. Especially for cancer patients who take long-term medication, drug cost has become an important consideration in treatment decisions. Therefore, many patients and their families will be cautious when choosing cosibelimab treatment options.

At present, cosibelimab's entry into the Chinese market mostly relies on imported drug channels or participation in patient welfare projects in clinical trials. Some large tertiary hospitals and specialized cancer centers are able to provide patients with this drug through special channels, but the quantity is limited and the price is higher. In response to the reality of not being covered by medical insurance, some patients choose to purchase their products overseas or receive treatment through international medical institutions. However, these approaches involve certain legal and logistical risks, and patients need to be carefully evaluated and conducted under the guidance of professional doctors.

In the future, with the accumulation of more clinical data and the advancement of domestic and foreign drug regulatory approval processes, cosibelimab is expected to be gradually included in China's medical insurance catalog. The inclusion in medical insurance will not only significantly reduce the financial burden on patients, but will also promote wider clinical application of the drug and benefit more cancer patients. At the same time, the country’s support policies for innovative drugs are increasingly improving, and relevant companies are actively promoting local production and registration applications to provide patients with more accessible treatment options.

Reference materials:https://www.drugs.com/